Hepatocellular carcinoma: Advances in systemic therapies
F1000Research · 07.05.2024 · 13 · 104
DOI: 10.12688/f1000research.145493.2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift F1000Research, online erschienen am 07.05.2024. Verfasst von Trevor Kwan-Hung Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Advanced hepatocellular carcinoma (HCC) is traditionally associated with limited treatment options and a poor prognosis. Sorafenib, a multiple tyrosine kinase inhibitor, was introduced in 2007 as a first-in-class systemic agent for advanced HCC. After sorafenib, a range of targeted therapies and immunotherapies have demonstrated survival benefits in the past 5 years, revolutionizing the treatment landscape of advanced HCC. More recently, evidence of novel combinations of systemic agents with distinct mechanisms has emerged. In particular, combination trials on atezolizumab plus bevacizumab and durvalumab plus tremelimumab have shown encouraging efficacy. Hence, international societies have revamped their guidelines to incorporate new recommendations for these novel systemic agents. Aside from treatment in advanced HCC, the indications for systemic therapy are expanding. For example, the combination of systemic therapeutics with locoregional therapy (trans-arterial chemoembolization or stereotactic body radiation therapy) has demonstrated promising early results in downstaging HCC. Recent trials have also explored the role of systemic therapy as neoadjuvant treatment for borderline-resectable HCC or as adjuvant treatment to reduce recurrence risk after curative resection. Despite encouraging results from clinical trials, the real-world efficacy of systemic agents in specific patient subgroups (such as patients with advanced cirrhosis, high bleeding risk, renal impairment, or cardiometabolic diseases) remains uncertain. The effect of liver disease etiology on systemic treatment efficacy warrants further research. With an increased understanding of the pathophysiological pathways and accumulation of clinical data, personalized treatment decisions will be possible, and the field of systemic treatment for HCC will continue to evolve.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
- State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
- Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
ORCID-Profile: Man-Fung Yuen
Zitieren
APA
Wu, T. K., Hui, R. W., Mak, L. Y., Fung, J., Seto, W. K., & Yuen, M. F. (2024). Hepatocellular carcinoma: Advances in systemic therapies. F1000Research, 13, 104. https://doi.org/10.12688/f1000research.145493.2
Vancouver
Wu TK, Hui RW, Mak LY, Fung J, Seto WK, Yuen MF. Hepatocellular carcinoma: Advances in systemic therapies. F1000Research. 2024;13:104. doi:10.12688/f1000research.145493.2
BibTeX
@article{Wu2024,
author = {Wu, Trevor Kwan-Hung and Hui, Rex Wan-Hin and Mak, Lung-Yi and Fung, James and Seto, Wai-Kay and Yuen, Man-Fung},
title = {Hepatocellular carcinoma: Advances in systemic therapies},
journal = {F1000Research},
year = {2024},
volume = {13},
pages = {104},
doi = {10.12688/f1000research.145493.2}
}
EUVIMED